Alfresa, JP3126340003

Alfresa Holdings stock flags lower operating income despite sales growth

Published on 11/20/2026 at 01:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Alfresa Holdings stock saw interim sales rise while operating income declined. The company kept its full-year forecast and annual dividend outlook unchanged.

Interim results point to margin pressure

  • Alfresa reported higher interim sales but lower operating income for the six months ended September 30, 2026.
  • Pharmaceutical wholesale sales remained firm, while drug price revisions and logistics costs weighed on profitability.
  • The full-year forecast was maintained, with the annual dividend outlook unchanged at 71 yen per share.
Alfresa, JP3126340003, Illustration mit AI erstellt.

Alfresa Holdings reported higher interim sales but a weaker operating result for the six months ended September 30, 2026. The company disclosed the figures on November 9, according to Japan IR.

Sales growth meets cost pressure

Net sales increased 3.5 percent to 1,582,760 million yen. Operating income fell 19.6 percent to 13,029 million yen, while interim net income attributable to owners of the parent declined 28.5 percent to 8,240 million yen.

The prescription-pharmaceutical wholesale business remained the main contributor to sales, but its operating income decreased 5.2 percent. Alfresa cited the impact of the April 2026 drug-price revision, distribution reforms and higher logistics costs, including personnel expenses.

Outlook remains unchanged

Alfresa maintained its full-year forecast for the fiscal year ending March 2027. The company also kept its annual dividend outlook at 71 yen per share and said its capital policy, including share buybacks, would continue.

The results leave investors weighing resilient healthcare demand against pressure on distribution profitability. New investments and regenerative-medicine-related businesses remain part of the group's expansion plans.

Medical distribution in Japan

Alfresa Holdings operates in medical distribution, with prescription-pharmaceutical wholesale as its largest business. Its activities also include self-medication wholesaling, manufacturing and pharmacy operations. The group is focused on the Japanese healthcare market.

Alfresa Holdings at a glance

  • Company: Alfresa Holdings Corporation
  • ISIN: JP3126340003
  • Tokyo ticker: 2784.T
  • Reporting period: Six months ended September 30, 2026
  • Net sales: 1,582,760 million yen
  • Operating income: 13,029 million yen
  • Interim net income: 8,240 million yen attributable to owners of the parent
  • Annual dividend outlook: 71 yen per share

Japan's equity market environment is covered through the Nikkei 225.

More news and analyses on Alfresa Holdings stock.

Disclaimer...
en | JP3126340003 | ALFRESA | boerse | 70538228 | bgmi